Orthovita, Inc.

Tissue engineering, biomaterials

Orthovita (NASDAQ NM:VITA) was founded in 1992 as a biomaterial company. Orthovita has developed proprietary technologies to manufacture synthetic biologically active tissue engineering products for restoration of the human skeleton. In order to commerzialise products based on VITOSS®, Orthovita collaborates with the Kensey Nash Corporation.

Antony Koblish, President, CEO
Albert J. Pavucek, Jr., CFO
Maarten Persenaire, CMO

David Fitzgerald, Chairman
R. Scott Barry
Morris Cheston, Jr.
Antony Koblish
Mary E. Paetzold
Paul G. Thomas
William E. Tidmore, Jr.
Paul T. Touhey, Jr.

45 Great Valley Parkway
Malvern, PA 19355
USA
Phone: +1-610-640 1775
Fax: +1-610-640 2603

The company’s synthetic biologically active tissue engineering products for restoration of the human skeleton include e.g. the following: VITOSS® Synthetic Cancellous Bone Void Filler is a resorbable scaffold made of beta-tricalcium phosphate for optimal resorption, cell seeding and ingrowth of host bone.

CORTOSS® Synthetic Cortical Bone Void Filler is a composite, which imitates the strength characteristics of human cortical bone. CORTOSS® is not available for sale in the United States and is limited to investigational use.

RHAKOSS® Synthetic Bone Spinal Implant is currently in the development phase, but is considered as a synthetic bioactive, bone-bonding alternative to titanium/carbon fiber cages and allograft cadaver bone implants.

IMBIBE™ Bone Marrow Aspirate Delivery Syringe is a system comprising VITOSS® in order to provide the ideal environment for cells to repairing defects in the spine, extremities and pelvis.

VITAGEL™ Surgical Hemostat is a safe adherent matrix and an impermeable barrier to blood flow.

Results of the ongoing study, “Clinical Experience Using A Novel Bio-Composite For Treating Vertebral Compression Fractures in Vertebroplasty and Kyphoplasty; Report On The First 40 Patients” were presented in July 2005.
A larger, prospective randomised controlled multi-center IDE study is underway in the U.S. designed to demonstrate that CORTOSS is safe and effective for the treatment of osteoporotic vertebral compression fractures.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.